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ABSTRACT Although the molecular defect causing
Duchenne/Becker muscular dystrophy (DMD/BMD)
was identiﬁed nearly 20 years ago, the development of
effective therapeutic strategies has nonetheless re-
mained a daunting challenge. Over the years, a variety
of different approaches have been explored in an
effort to compensate for the lack of the DMD gene
product called dystrophin. This review not only pre-
sents some of the most promising molecular, cellular,
and pharmacological strategies but also highlights some
issues that need to be addressed before considering
their implementation. Speciﬁcally, we describe current
strategies being developed to exogenously deliver
healthy copies of the dystrophin gene to dystrophic
muscles. We present the ﬁndings of several studies that
have focused on repairing the mutant dystrophin gene
using various approaches. We include a discussion of
cell-based therapies that capitalize on the use of myo-
blast or stem cell transfer. Finally, we summarize the
results of several studies that may eventually lead to the
development of appropriate drug-based therapies. In
this context, we review our current knowledge of the
mechanisms regulating expression of utrophin, the
autosomal homologue of dystrophin. Given the com-
plexity associated with the dystrophic phenotype, it
appears likely that a combinatorial approach involving
different therapeutic strategies will be necessary for the
appropriate management and eventual treatment of
this devastating neuromuscular disease.—Chakkalakal,
J. V., Thompson, J., Parks, R. J. Jasmin, B. J. Molecular,
cellular, and pharmacological therapies for Duchenne/
Becker muscular dystrophies. FASEB J. 19, 880–891
(2005)
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Duchenne muscular dystrophy (DMD) is a severe
degenerative disorder of skeletal and cardiac muscles
that affects 1 in 3500 male births (1). DMD patients
characteristically display progressive muscle weakness,
which begins in early childhood (2). Although DMD is
present at birth, clinical symptoms are not evident until
3–5 years of age (3). Initial symptoms include leg
weakness, increasing convex curvature of the spine, and
a waddle-like gait (3). Continuous muscle wasting re-
sults in progressively weaker muscles, usually leaving
DMD patients wheelchair bound by the age of 11 or 12
(4). Affected individuals usually succumb to the disease
by the second or third decade of life (4). A similar, yet
milder, dystrophy known as Becker muscular dystrophy
(BMD) is more variable phenotypically and generally
follows a less severe course than DMD (5).
Although two decades have now past since the iden-
tiﬁcation of the molecular defect involved in DMD,
there are still no effective cures to signiﬁcantly alter the
relentless progression of the disease. The lack of an
effective therapeutic regimen can in large part be
explained by the inherent difﬁculties associated with
replacing or repairing the diseased gene and the mul-
tifaceted nature of the symptoms that range from
degeneration of muscle ﬁbers to detrimental immune
response. Collectively, these various difﬁculties and
issues hinder the development of therapies aimed at
correcting the molecular defect or promoting muscle
cell survival. In this review, we will highlight several
therapeutic strategies currently under intense investi-
gation.
DMD AND DYSTROPHIN GENE PRODUCTS
Twenty years ago the genetic defect underlying DMD
was mapped to chromosome Xp21 in humans (for a
review, see refs 6, 7). This gene is the largest identiﬁed
to date, which could account for its relatively high
frequency of mutation and incidence of DMD (8). The
DMD gene product is known as dystrophin (6, 9, 10).
The large DMD gene can accommodate production of
several dystrophin isoforms through alternative pro-
moter usage and splicing of pre-mRNA. The predomi-
nant dystrophin isoform found in skeletal and cardiac
muscles is an 427 kDa cytoskeletal protein predicted
to contain 3685 amino acids. Full-length dystrophin is
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N-terminal “actin binding” domain; 2) a middle “rod”
domain consisting of spectrin-like repeats (11); 3) a
cysteine-rich domain; and 4) a carboxyl-terminal do-
main (10) (Fig. 1A). Two additional isoforms are
considered to be full-length and are expressed in the
brain (12, 13). Four other variants contain unique ﬁrst
exons, giving rise to dystrophin proteins of 260 kDa
(14), 140 kDa (15), 116 kDa (16), and 71 kDa (17, 18).
These shorter isoforms lack the actin binding domain,
which suggests they may have other functions different
from those ascribed to full-length dystrophin.
In skeletal muscle ﬁbers, full-length dystrophin accu-
mulates predominantly at the cytoplasmic face of the
sarcolemma (19, 20). The distribution of dystrophin
along muscle ﬁbers is rather homogeneous, thereby
creating a submembranous mesh of dystrophin mole-
cules. Mutations and/or deletions in the dystrophin
gene, as seen in DMD patients, prevent the production
of dystrophin and lead to its complete absence in
muscle ﬁbers (9). In BMD, however, the nature of the
mutations/deletions are such that they allow for syn-
thesis of a truncated yet partly functional dystrophin
molecule, likely explaining the milder phenotype ob-
served for BMD patients (5).
At the sarcolemma, dystrophin is part of a macromo-
lecular group of proteins collectively referred to as the
dystrophin-associated protein complex (DAP) (21)
(Fig. 2). Several key components of this complex have
been well studied in recent years, and their interaction
patterns and organization support the notion that
dystrophin serves to link the intracellular microﬁla-
ment network of actin to the extracellular matrix (21,
22). The absence of dystrophin at the sarcolemma
results in a dramatic change in the level and localiza-
tion of the dystrophin complex. For example, studies
have reported marked reductions in the overall levels
of DAPs in dystrophin-deﬁcient skeletal muscle from
DMD patients and animal models such as the mdx
mouse (23, 24). These data indicate that the absence of
dystrophin ensues the loss of DAPs at the sarcolemma.
The absence of this physical link between the interior
and exterior of the muscle cell renders the sarcolemma
fragile, making muscle ﬁbers susceptible to degenera-
tion during repeated cycles of muscle contraction and
relaxation. Support for this model stems primarily from
observations showing an increased sensitivity of mdx
muscle ﬁbers to mechanical stress (25, 26). Mutations
in the genes that encode some DAPs also cause various
forms of muscular dystrophies (for a review, see refs 27,
28). Therefore, dystrophin and its associated proteins
assume speciﬁc functions at the sarcolemma that are
crucial to the survival of muscle ﬁbers.
Nonstructural roles have been described for dystro-
phin, making it a multifunctional protein. The localiza-
tion of dystrophin and its associated components at the
sarcolemma places them at an appropriate position to
serve as a signaling scaffold that is responsive to extra-
cellular stressors. For example, binding of the extracel-
lular matrix ligand laminin to -dystroglycan results in
the recruitment of signaling molecules involved in
actin remodelling, such as Rac1 (29). Several other
signaling molecules interact with components of the
dystrophin complex, including NOS, Grb2, and diacyl-
Figure 1. Schematic diagram of dystrophin and dystrophin-
related proteins. A) Shown are the four main domains of
full-length dystrophin: the actin binding domain, rod domain
(26 spectrin-like repeats), cysteine-rich domain and C termi-
nus domain. The cysteine-rich domain and carboxyl terminus
are found in all the isoforms. Name and molecular mass are
indicated for each dystrophin isoform. B) Comparison of
dystrophin and utrophin. Note that all domains of dystrophin
are present in utrophin.
Figure 2. Schematic representation of dystrophin localization
in muscle ﬁbers. Dystrophin is found throughout the sarco-
lemma of adult muscle ﬁbers as well as at the troughs of
neuromuscular junctions. Dystrophin is thought to link cy-
toskeletal actin ﬁlaments to the extracellular matrix via a
complex comprised of DAP. This complex consists of dystro-
glycans (, ), sarcoglycans (, , , , ε ), sarcospan, syntro-
phins (, ), dystrobrevins, and NOS.
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ing to a role for the dystrophin complex in localizing
signaling mediators argues in favor of the notion that
this function may be important in stimulating appro-
priate downstream cascades in response to various
extracellular stimuli. Naturally, these signaling events
would not function correctly in a dystrophin-deﬁcient
muscle, which likely contributes to the disease pathology.
Dystrophin has been proposed to play a role in
calcium homeostasis. In mdx mice and DMD patients,
intracellular calcium levels are elevated relative to
normal controls (33, 34). In cultured DMD and mdx
myotubes, increased leak channel activity, affecting the
calcium permeability of the sarcolemma, has been
reported (33, 35, 36). Young mdx diaphragm muscles
isolated before the onset of signiﬁcant pathology show
enhanced calcium inﬂux through calcium/stretch-acti-
vated channels, resulting in the aberrant hyperactiva-
tion of signaling cascades involved in the inﬂammatory
response (37). Elevated expression of inﬂammatory
mediators and chemoattractants has been observed to
occur in dystrophin-deﬁcient muscles prior to the onset
of major disease symptoms (38–40). This apparent
sensitivity of dystrophic muscle in triggering inﬂamma-
tion due to aberrant calcium homeostasis may be
detrimental to muscle cell survival and to the potential
introduction of therapeutics.
MOLECULAR THERAPIES TO TREAT DMD
DMD is a monogenic disorder in which the absence of
full-length dystrophin leads to the characteristic fea-
tures of the disease. To assess whether expression of
dystrophin in a dystrophic model could reverse the
disease symptoms, transgenic mdx mice bearing a full or
minidystrophin transgene were generated (41–43).
These mice do not display the characteristic dystrophic
pathology. Transgenic mdx mice expressing full-length
dystrophin show no sign of the muscle pathology even
when dystrophin is expressed at 70% of normal levels
(42, 44). Even low level of dystrophin expression can
result in some disease correction, suggesting that par-
tial restoration of dystrophin levels leads to signiﬁcant
improvements (42, 45). Collectively, these results indi-
cate that the reintroduction of dystrophin into dystro-
phin-deﬁcient muscles can restore proper muscle func-
tion. Over the last several years, a number of strategies
have been examined to achieve this.
Dystrophin gene delivery
Perhaps the most direct method for introducing a
functional dystrophin gene into dystrophin-deﬁcient
muscle is through gene replacement or “gene therapy.”
The simplest form of gene therapy consists in injecting
plasmid DNA encoding dystrophin directly into muscle
(46). Although such gene delivery is typically not
efﬁcient, it bypasses the disadvantages linked to viral
vectors that are notorious for triggering a strong anti-
vector immune response. Intramuscular or intrave-
nous/arterial injection of a therapeutic plasmid into
mdx mice can result in expression of dystrophin in up to
10% of the muscle ﬁbers, concurrent with the correct
localization of the protein (and at least some of the
DAPs), and an increase in peripheral nuclei (47–50). In
one plasmid-based study, dystrophin could be detected
for at least 6 months after a single administration,
although an antibody response, but no cellular re-
sponse, was developed against the newly synthesized
dystrophin protein (50). These encouraging results led
to the initiation of a phase 1 clinical trial involving
plasmid-mediated delivery of dystrophin cDNA to the
radial muscle (51). In this trial, a low level of dystrophin
expression was detected for up to 3 wk in muscle ﬁbers
of six of nine patients (52). No adverse effects were
noted. Although a limited amount of dystrophin was
detected in the injected muscles, this study remains an
important ﬁrst step in moving dystrophin gene replace-
ment therapy into the clinic.
An alternative gene therapy approach for delivering
the dystrophin gene to dystrophic ﬁbers is through the
use of viral vectors. To date, most studies have used
either adenovirus or adeno-associated viral vectors for
delivery of dystrophin, each system having distinct
advantages or disadvantages. Adenovirus (Ad) vectors
have a fairly large cloning capacity (8 kb in traditional
early region 1 (E1) -deleted vectors), and were the ﬁrst
viral vector system to successfully deliver a truncated
dystrophin cDNA (6.3 kb) to mdx mice (53). Ad-
mediated delivery of dystrophin yielded promising re-
sults, including restoration of the dystrophin complex
and improvements in several physiological parameters.
However, these vectors have inherent limitations, in-
cluding activation of undesirable cellular and humoral
immune responses, transient gene expression, and the
inability to carry large genes, which together limit their
usefulness for applications requiring long-term correc-
tion. Several of these limitations have been overcome in
a newer generation of Ad vector termed helper-depen-
dent Ad (hdAd), which are deleted of all viral protein
coding sequences. hdAd have some important advan-
tages over E1-deleted Ad such as a reduced immune
response, improved transgene expression, and larger
insert carrying capacity (up to 36 kb; refs 54, 55). Thus,
hdAd are very promising vectors for gene delivery, and
are being evaluated in a variety of animal models of
human disease, including DMD.
Studies using hdAd to deliver dystrophin to mdx mice
have shown the restoration of the dystrophin complex
at the sarcolemma, long-term expression of dystrophin
and correction of pathological and physiological indi-
ces of muscle disease, particularly in neonatal mice (45,
56, 57). Successful treatment of adult mdx mice with
E1-deleted Ad or hdAd vectors has been more prob-
lematic, due in part to inefﬁcient infection of mature
muscle by Ad. The natural cell surface receptor for Ad,
the coxsackie-adenovirus receptor (CAR), is develop-
mentally down-regulated on muscle cells, preventing
Ad from efﬁciently attaching to, and infecting, mature
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receptors, such as heparan sulfate proteoglycans, which
are prevalent on many cell types including muscle, can
enhance Ad transduction (59). However, infection of
juvenile animals whose muscles have already endured
major cycles of degeneration and regeneration resulted
in minimal improvements in pathological indices when
compared with neonatal animals (59), suggesting that,
to be successful, gene therapy for DMD must be initi-
ated early, before the onset of major disease symptoms.
Despite the improvements in Ad vector design, sig-
niﬁcant problems still remain. For example, injection
of high doses of E1-deleted or hdAd leads to the
induction of innate and inﬂammatory immune re-
sponses and, at very high doses, direct toxicity, which
can be lethal (60, 61). Many researchers are investigat-
ing methods to reduce Ad-induced inﬂammation and
toxicity, such as coating the virus with polyethylene
glycol, which serves to mask Ad epitopes from the
immune system (62). Although the use of hdAd does
reduce the adaptive immune response to the viral
vector (60), generation of immunity to the delivered,
therapeutic protein in the dystrophin-naive mice re-
mains a concern, and will likely be a confounding
factor as these therapies proceed into the clinic. Early
gene therapy studies involving codelivery of immune-
modulatory molecules such as CTL4AIg, which blocks
costimulatory signals between T cells and antigen pre-
senting cells (63), have been re-examined in the con-
text of hdAd-mediated dystrophin delivery to muscle
and can prolong dystrophin expression in immuno-
competent mice (64, 65). It is hoped that through these
varied approaches, immune responses to the Ad vector
and therapeutic protein can be minimized, or elimi-
nated, resulting in a greater therapeutic index.
The second class of viral vector that has received
considerable attention of late is adeno-associated virus
(AAV). AAV vectors are characterized by reduced im-
munological and inﬂammatory responses in vivo com-
pared with Ad. Unfortunately, AAV vectors have a
cloning capacity of only 4 kb, and cannot accommo-
date a full-length dystrophin cDNA. However, recent
advances in the creation of mini- and microdystrophin
genes have resulted in dystrophin expression cassettes
that can be packaged in the AAV capsid (66–68).
Delivery of AAV-microdystrophin to mdx mice can
result in widespread transduction and improved muscle
function. Indeed, a recent study showed that a single
systemic injection of an AAV-dystrophin resulted in
transduction of virtually every skeletal and cardiac
muscle groups of an adult mouse (68). However, it has
yet to be determined if these minimal dystrophin
proteins fully compensate for the lack of full-length
dystrophin, as these proteins may only serve to convert
a DMD patient into a phenotypic BMD patient.
Taken together, these studies show that gene therapy
through the use of viral vectors appears promising in
the treatment of DMD. Over the next few years, im-
provements in vector design and/or delivery will hope-
fully result in more efﬁcient gene replacement thera-
pies. Already, the use of viral vectors, in combination
with other therapies designed to aid in the correction
of mutated dystrophin leading to the production of
functional protein, has shown some rather promising
results (see below).
Correction of mutant dystrophin
Chimeric RNA/DNA oligonucleotides can be used to
direct the correction of a mutation by inducing prefer-
ential gene conversion from a mutant to a functional
allele (69–71). These oligonucleotides are homologous
to a targeted gene, yet include one mismatched base
(72). Binding of the chimeric oligonucleotide to the
mutant gene stimulates the cell to “repair” the defective
gene based on the correct sequence contained in the
oligonucleotide. Injection of chimeric oligonucleotides
designed to correct the point mutation underlying the
genetic defect seen in mdx mice, resulted in the expres-
sion of dystrophin in muscle ﬁbers surrounding the site
of injection (73). Further characterization of this treat-
ment showed that the resultant dystrophin protein
expressed in these mice was full-length and included all
the coding exons surrounding the mutation site (73). A
more recent study conﬁrmed these earlier results in
vitro as well as in vivo (74), and determined that gene
conversion had indeed occurred at the target DNA site
in cultured cells.
Although chimeraplast-mediated therapy was initially
designed to correct point mutations, which constitute
40% of DMD mutations (75), a recent study has ex-
tended the utility of this approach to correct mutations
that disrupt the translational reading frame, which
account for a majority of DMD defects (76). In this
study, restoration of the translational reading frame
involved targeting the exon/intron boundaries of the
mutated exon 23 in mdx mice, resulting in skipping/
removal of this exon and production of a truncated yet,
functional protein. The rationale for inducing exon
skipping stems from two important observations. First,
whereas muscle ﬁbers from DMD patients contain
essentially no functional dystrophin protein, ﬁbers
from BMD patients possess partially functional dystro-
phin that results from in-frame deletions (5). Second,
although muscles from DMD patients and mdx mice
basically contain no dystrophin, a few “revertant” ﬁbers
that express dystrophin are occasionally seen, thought
to result from frame-restoring exon-skipping (77, 78).
Despite these advances, several aspects need to be
resolved before chimeric oligonucleotides may be con-
sidered in a clinical setting. Since the frequency of gene
conversion is rather modest and varies among different
cell types, it becomes imperative to establish the bene-
ﬁcial dosage of chimeric oligonucleotides and whether
multiple injections are required to obtain therapeutic
levels of gene conversion. In addition, although this
approach demonstrates some degree of molecular cor-
rection, more data are required concerning functional
aspects of the correction in vivo.
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proach involves inducing exon skipping through the
use of antisense oligonucleotides (AOs) that target
transcribed RNA molecules. In a recent study, direct
intramuscular injection of AOs resulted in a signiﬁcant
increase in the number of dystrophin-positive ﬁbers
(20%) in mdx mouse muscle (79). In this case, the
newly expressed dystrophin contained both N- and
C-terminal domains, which therefore led to the resto-
ration of the dystrophin complex (79). The expression
of dystrophin persisted for up to 2 months after the
initial injection and resulted in improved force produc-
tion. This therapy was not associated with autoimmune
or humoral immune responses to the AOs.
Recently, a systemic delivery and direct injection of a
single dose of AAVs carrying modiﬁed AOs linked to
small nuclear RNAs to improve correction of targeted
mRNAs, was shown to result in widespread expression
of functional dystrophin in 50–80% adult mdx muscle
ﬁbers (44). This widespread expression of dystrophin
was shown to persist for  3 months and led to
improved muscle morphology, correct localization of
some DAPs, and increased resistance to forced length-
ening contractions. Based on these encouraging re-
sults, the use of AOs in combination with AAVs holds
potential as a systemically delivered therapy that can
correct the primary defect seen in DMD. One distinct
drawback to this approach is that it would only be
useful to those patients that contain mutations primar-
ily in regions of the gene that, if excised (or “skipped”),
would not severely compromise the function of the
resulting dystrophin protein. Thus, oligonucleotide-
and antisense-based therapies may only be applicable to
a subset of DMD patients.
CELL-BASED THERAPIES
Cell-based therapies involve the delivery of normal cells
to the dystrophic muscle, with the hope that the
delivered cells will fuse or repopulate the dystrophic
muscle, thereby improving muscle pathology and func-
tion. The ﬁrst attempts at a cell-based therapy consisted
of grafting a normal muscle into a dystrophic recipient
muscle bed (80, 81). An initial study using this ap-
proach showed nearly normal contractile properties in
adult dystrophic hosts after implantation of a muscle
graft, suggesting that muscle transplantation may in-
deed be a viable treatment (81). However, some ethical
issues make this form of treatment difﬁcult to pursue
particularly the required use of newborn muscle in
order to overcome problems seen with adult tissues,
including appropriate reinnervation and revasculariza-
tion.
A second, more promising cell-based approach is
myoblast transfer, a procedure that involves injecting or
transplanting donor muscle precursor cells (myoblasts)
into a dystrophic host. The goal of myoblast transfer is
to allow fusion of donor, dystrophin-positive myoblasts
with host, dystrophin-deﬁcient muscle ﬁbers, thereby
inducing expression of dystrophin. Injected myoblasts
can indeed fuse into host mdx myoﬁbers and can result
in dystrophin expression at 30–40% of normal levels.
Despite some promising results, myoblast transfer has
many obstacles to overcome before it becomes a suit-
able therapeutic approach. These obstacles include
attaining sufﬁcient distribution and fusion of donor
cells with host muscle ﬁbers, extending the donor
myoblast survival period (since many cells die soon
after transplantation), and eliminating the immune
response to donor myoblasts or newly synthesized dys-
trophin protein (82). Human clinical studies using
myoblast transfer were performed on DMD patients
many years ago, despite a lack of evidence fully support-
ing the effectiveness of this treatment. Even with mul-
tiple injection sites, the efﬁciency of myoblast transfer
was very low and failed to improve muscle strength in
the patient group (83–85). Skuk and colleagues (86–
88) have been performing similar studies of nonhuman
primates with the goal of improving the efﬁciency of
myoblast engraftment. Several different parameters
have been examined in an attempt to increase the
efﬁciency of myoblast transfer including the use of
various immunosuppressive agents, myotoxins and mul-
tiple injection protocols.
A recent strategy that has been explored to improve
the efﬁciency of myoblast transfer and/or gene deliv-
ery, is the use of genetically modiﬁed myoblasts in ex
vivo based therapies. In this approach, myoblasts from
DMD patients are isolated, modiﬁed genetically, then
reintroduced into the patient. Genetic modiﬁcation
can include introduction of the dystrophin gene, or
antisense-based methodologies designed to enhance
the proliferative capacities of myoblasts (89, 90). Ex
vivo based approaches, although displaying some ca-
pacity to improve myoblast transfer, still require further
optimization particularly to circumvent host immune
responses to the delivered cells and to develop more
efﬁcient injection protocols.
An alternative cell-based method to myoblast transfer
is the systemic delivery of precursor cells with myogenic
potential. The feasibility of this approach came with the
discovery of a population of cells identiﬁed via FACS
analysis and based on their ability to exclude the
ﬂuorescent dye Hoescht (91). These multipotential
cells, referred to as side population (SP) cell, can be
derived from different tissues including bone marrow
and muscle. SP cells demonstrate a clear plasticity to
myogenic and hematopoietic lineages (92). The discov-
ery of SP cells suggested the existence of progenitor
cells that could be systemically delivered to dystrophic
recipients to subsequently give rise to muscle cells in a
myogenic environment. In initial studies, intravenous
injection of isolated SP cells from marrow and muscle
into mdx mice, led to the incorporation of donor nuclei
within existing muscle ﬁbers and to the expression of
dystrophin (92). Unfortunately, the frequency of incor-
poration of donor nuclei and the level of dystrophin
expression were rather low and did not result in major
therapeutic beneﬁts. In a related study, examination of
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a bone marrow transplant revealed the presence of
donor-derived nuclei and dystrophin-positive ﬁbers 13
years after the bone marrow transplant (93). Although
the dystrophin present in this case was a truncated
version, and the source of expression remains to be
determined, these results are clearly encouraging as
they showed that fusion of donor-stem cells and dystro-
phin expression can persist for many years (93). To
improve on the persistence and modest level of dystro-
phin expression, SP cells have been exploited for use as
a systemic carrier in ex vivo-based therapies. This
property was recently tested through the use of SP cells
transduced with lentiviral vectors containing microdys-
trophin (94). These experiments demonstrated low
levels of incorporation of the modiﬁed cells into dys-
trophic myoﬁbers and successful expression of the
transgene (94).
An issue that remains to be resolved is the contro-
versy surrounding the potential plasticity of SP cells.
Recently, Asakura et al. demonstrated an intrinsic lack
of myogenicity of SP cells despite containing markers
that could specify potential lineage commitment to-
ward myeloid or myogenic fates (95). However, these
cells were able to undergo myogenic differentiation
when cocultured with myoblasts or upon injection into
regenerating muscle (95), suggesting that for SP cells
to undergo myogenic commitment, they require the
environment provided by myogenic cells. To further
examine the issue of SP cell plasticity, Camargo et al.
puriﬁed SP cells with markers indicative of hematopoi-
etic and myogenic plasticity. They also observed that
regeneration and inﬂammation were required for the
incorporation of these cells into muscle ﬁbers (96).
Using different morphological and functional parame-
ters, this study suggested that the incorporation of
donor bone marrow and SP cells into regenerating,
inﬂamed myoﬁbers may in fact stem from spontaneous
fusion of myeloid progeny with existing ﬁbers, and
their subsequent transformation to the myogenic lin-
eage is caused by the presence of regulatory factors
from neighboring myonuclei (96). Spontaneous myo-
genic differentiation of cells derived from different
tissues including bone marrow has been previously
observed and deemed to be inefﬁcient as a therapeutic
strategy for DMD treatment (reviewed in ref 97). Al-
though the idea of isolating multipotent progenitor
cells that can give rise to myogenic progeny is quite
appealing, a great deal of work is still required to
further characterize these cells before clinical trials can
be envisioned.
PHARMACOLOGICAL APPROACHES
Over the years, several pharmacological interventions
have been proposed as potential treatments for DMD/
BMD. Various compounds such as allupurinol (98),
vitamin E (99) and selenium as well as mazindol, a
growth hormone inhibitor (100, 101), were deemed
ineffective or not beneﬁcial against the progression of
DMD. Despite these drawbacks, there has been a con-
tinued focus in trying to identify compounds that can
improve functional and morphological aspects of DMD
muscle. Concurrent with improved morphology of ex-
isting ﬁbers, the identiﬁcation of prophylactics that can
improve the regenerative process may be effective in
delaying the onset of DMD pathology.
Myostatin and glucocorticoids
Studies aimed at the manipulation of satellite cell
function have identiﬁed potential drug-based thera-
pies. Satellite cells are quiescent myogenic precursor
cells residing at the interface between the basal lamina
and sarcolemma. Satellite cells have the capacity to give
rise to myoblasts that partake in the normal develop-
ment of myoﬁbers. These normally quiescent cells can
give rise to myoblasts that can migrate to sites of muscle
injury and fuse with existing myoﬁbers to maintain
muscle mass. Unlike satellite cells puriﬁed from normal
muscle ﬁbers, DMD satellite cells display an intrinsic
defect in proliferative capacity that is exasperated with
age, thus partially explaining the progressiveness of
muscle wasting seen as DMD patients mature (102).
One paradigm that may improve the proliferative
capacity of DMD satellite cells is blocking the function
of myostatin (MSTN). Myostatin (GDF-8) is a TGF-
family member that is a negative regulator of skeletal
muscle growth, as evidenced by the increased muscula-
ture of animals with inactivating mutations in this gene
(103–105). Although the mechanism whereby MSTN
mutations result in enhanced muscle mass remains to
be fully characterized, a recent report attributed this
muscle gain to delayed differentiation coupled with
enhanced activation, renewal, and proliferative capaci-
ties of MSTN
/ satellite cells (106). Myostatin block-
ade in mdx mice results in increased body weight,
muscle mass, and size, as well as in an increase in
muscle strength (107). A signiﬁcant reduction in mus-
cle ﬁber degeneration and serum creatine kinase levels
was observed in treated animals suggesting that some
degree of functional improvements had occurred
(107). Similarly, mdx/MSTN
/ double mutant mice
display an improved phenotype (108). The mechanism
whereby MSTN improves muscle function is not known
but appears not to involve an increase in the expression
of the dystrophin homologue called utrophin (107).
Although it seems paradoxical to increase the amount
of dystrophic muscle in DMD patients, these preclinical
results showing improvements in mdx mice clearly lend
support to investigating further the usefulness of this
approach.
Glucocorticoids, such as prednisone, are effective in
slowing the progression of DMD (109–111). Despite
the promise of prednisone as an effective therapy to
combat DMD pathology, the potential for side effects
has limited the widespread use of this drug. In contrast,
the prednisone-derivative deﬂazacort appears to pro-
vide an effective alternative with less severe side effects
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resulted in improved pulmonary function, suggesting
an improvement in the function of respiratory muscles
(114). Deﬂazacort treatment of mdx diaphragms was
shown to improve the growth and repair process of this
respiratory muscle (115). Some of the beneﬁcial effects
of deﬂazacort are due to its ability to promote laminin
expression, myoblast fusion, and myogenic differentia-
tion in mdx mice, all suggestive of improved satellite cell
function (115–117). Subsequent studies correlated the
beneﬁcial effects of deﬂazacort with the elevated ex-
pression of the muscle-speciﬁc isoform of nitric oxide
synthase. Consistent with these observations, treatment
of mdx mice with deﬂazacort and the NO donor l-
arginine resulted in greater morphological improve-
ments (117). Recent studies have provided new mech-
anistic insights into how deﬂazacort may mediate these
effects (see below).
Treatment with antibiotics
Some mutations causing DMD are due to the formation
of a premature stop codon within the coding sequence
of dystrophin, and a recent study examined whether
inducing stop codon read-through could result in res-
toration of dystrophin expression (118). Aminoglyco-
side treatment of cultured cells can cause suppression
of stop codons by extensive misreading of RNA codes
(118, 119), and insertion of alternative amino acids in
place of the stop codon. Since the defect in the mdx
mouse is caused by a mutation that introduces a
premature stop codon, Sweeney and colleagues sought
to determine whether treatment of these mice with
gentamicin, an aminoglycoside antibiotic, could lead to
the synthesis of dystrophin in muscle ﬁbers (118).
Indeed, muscles of mdx mice treated with this antibiotic
showed increased sarcolemmal expression of dystro-
phin and restoration of some components of the dys-
trophin complex together with improved resistance to
lengthening contractions (118). However, dystrophin
levels were 10–20% of normal mouse muscle, suggest-
ing that misreading of RNA codes through this ap-
proach cannot completely restore dystrophin expres-
sion (118). Nonetheless, this level of dystrophin
expression was sufﬁcient to protect the muscles from
contraction-induced damage.
Due to the negative reports from human trials using
gentamicin (120), a recent study tried to replicate some
of the results from the initial animal study (121). In
contrast to earlier ﬁndings, no increase in dystrophin
expression was observed. The authors of this study
proposed that differences in the treatment protocol
may account for this divergence. Clearly, additional
experimentation is warranted to determine the effec-
tiveness of this approach for treating DMD.
Up-regulation of a dystrophin-related protein
The aforementioned gene-based treatments share a
variety of constraints stemming from immunological
responses triggered by the induction of dystrophin
expression. The proposed pharmacological treatments
suffer from potential adverse side effects, and lack of a
clear understanding of the mechanisms whereby some
of these interventions result in functional beneﬁts. An
alternative approach that could evade the negative
impact of the immunological reaction, and provide a
deﬁned target, involves up-regulating a protein of
therapeutic beneﬁt that is expressed endogenously in
dystrophic muscle. The premise of this approach is that
the up-regulated protein could compensate for the lack
of dystrophin by assuming some, or even all, of its
functional roles. One such protein is the nonmuscle
dystrophin isoform Dp71. However, expression of this
dystrophin isoform in mdx mouse muscle failed to
alleviate the dystrophic phenotype, indicating that
Dp71 cannot compensate for the lack of full-length
dystrophin (122, 123). These results indicate that C-
terminal isoforms cannot replace dystrophin or miti-
gate the dystrophic pathology. These data indicate that
the amino and carboxyl terminals of dystrophin are
both required for its function, and homologous regions
must be contained in any dystrophin-related protein
that is considered for DMD treatment.
The only protein containing both homologous ter-
minals to dystrophin is the dystrophin-related protein
1, now referred to as utrophin (Fig. 1). The overall
structure of dystrophin and utrophin are indeed simi-
lar, with the C and N termini displaying the greatest
homology, and greater divergence of sequence in the
central, rod domain (124). In addition to this signiﬁ-
cant homology, utrophin can associate with DAP,
thereby serving as a link between the actin ﬁlament
network and the extracellular matrix (125). Despite
these structural similarities, the pattern of expression of
dystrophin and utrophin in skeletal muscle differs
markedly. Whereas dystrophin is found along the en-
tire length of the sarcolemma, utrophin preferentially
accumulates at the neuromuscular (126–128) and myo-
tendinous junctions (127).
Due to the genetic and functional similarities be-
tween these two proteins, a number of studies have
tested the hypothesis that utrophin overexpression
along the length of dystrophin-deﬁcient muscles may
correct dystrophic symptoms. Accordingly, the expres-
sion of full-length or truncated utrophin in muscles
from transgenic mdx mice can lead to signiﬁcant im-
provements in mechanical functions and prevention of
the dystrophic pathology (129, 130). In theory, using
utrophin as opposed to dystrophin would be more
advantageous since utrophin is normally expressed in
mdx and DMD muscles, and no anti-transgene immune
response should be induced. Overexpression of utro-
phin using Ad vectors in muscles of mdx mice and
dystrophin-deﬁcient dogs led to a homogeneous distri-
bution of utrophin throughout transduced muscle ﬁ-
bers, as well as to the restoration of DAP (131, 132)
without any detectable immune response to the intro-
duced transgene (132). Taken together, these studies
clearly support the hypothesis that up-regulation of
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phic muscle ﬁbers is a plausible therapeutic avenue.
Accordingly, it becomes imperative to elucidate the
mechanisms presiding over utrophin expression in
muscle.
There are two different full-length utrophin iso-
forms, termed A and B (133, 134). A recent study
established that these isoforms are expressed in a
tissue-speciﬁc manner, with the A protein being the
abundant isoform in skeletal muscle (133, 134). Al-
though little is known about the mechanisms regulat-
ing expression of utrophin B, some events regulating
expression of utrophin A have been identiﬁed. Results
from several studies led to the idea that the synaptic
accumulation of utrophin in muscle occurs as a result
of the release of neurally secreted factors such as agrin
and heregulin, whose coordinate activities appear to
stimulate transcription of the utrophin gene in myonu-
clei located in the vicinity of the postsynaptic apparatus
(135–137). Downstream mediators of agrin and
heregulin signaling likely include members of the
ras-MAP kinase pathway that can phosphorylate the
ets-related transcription factor GABP. GABP is then
able to bind to the N-box motif located in the utrophin
A promoter, thereby stimulating local transcription
(135–138; for a review, see ref 139) (Fig. 3). Introduc-
tion of small peptides designed to stimulate heregulin-
based signaling in dystrophic mdx diaphragms has been
shown to result in signiﬁcant improvements in the
dystrophic pathology (140). The positive effects of
stimulated heregulin signaling on mdx muscles were
speciﬁcally attributed to utrophin induction, since mice
deﬁcient in dystrophin and utrophin maintained their
diseased phenotype (140).
Recently it was shown that stimulation of cal-
cineurin/NFAT signaling can lead to increased extra-
synaptic expression of utrophin A through transcrip-
tional, and possibly post-transcriptional, mechanisms
(141, 142) (Fig. 3). Overexpression of a constitutively
active form of calcineurin in muscles of mdx mice
increased utrophin A expression and led to restoration
of DAP at the sarcolemma and an attenuation of the
dystrophic pathology (143). In agreement with these
ﬁndings, treating mdx mice with the calcineurin inhib-
itor and immunosuppressant cyclosporine A can in fact
accelerate the development of dystrophic pathology
(144). Treatment of mdx mice with NO donors also
results in enhanced expression and the sarcolemmal
appearance of utrophin with concomitant morpholog-
ical corrections of muscle (145). As mentioned, deﬂaza-
cort has been demonstrated to improve muscle mor-
phology and enhance the activity of the NO pathway.
Recently, deﬂazacort has been shown to stimulate cal-
cineurin/NFAT signaling and utrophin expression,
with correlated improvements in dystrophic pathology
(146). Collectively, these studies suggest that an in-
creased understanding of the ability of deﬂazacort to
stimulate gene expression has relevance for the design
of therapies that can improve intrinsic defects in DMD
muscle development and increase expression of utro-
phin to functionally compensate for dystrophin.
CONCLUSIONS AND PERSPECTIVE
Initially it was thought that the characterization of the
molecular defects causing DMD and the identiﬁcation
of dystrophin would soon result in a cure for this
progressive neuromuscular disorders. Almost 20 years
have passed since the discovery of the gene and,
unfortunately, we have yet to ﬁnd an effective therapy
that could mitigate the dystrophic process. Although
numerous approaches are currently being explored,
many suffer from a variety of drawbacks. It is only
through additional research that these barriers will be
overcome and ultimately lead to the development of
therapeutic strategies effective in stemming the pro-
gressive and multifactorial nature of DMD. A clear
possibility is that the effective management and therapy
of DMD may only be achieved through a combination
of approaches. Thus, it is imperative to initiate studies
assessing the potential beneﬁcial impact of multiple
strategies combined into a single preclinical trial.
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